Natural History of Asymptomatic Left Ventricular Systo

Circulation

108, 977-982

DOI: 10.1161/01.cir.0000085166.44904.79

Citation Report

#	Article	IF	CITATIONS
1	Multi-Ethnic Study of Atherosclerosis: Objectives and Design. American Journal of Epidemiology, 2002, 156, 871-881.	3.4	3,068
2	Myocardial performance index, a Doppler-derived index of global left ventricular function, predicts congestive heart failure in elderly men. European Heart Journal, 2004, 25, 2220-2225.	2.2	104
3	Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction. Circulation, 2004, 109, 3176-3181.	1.6	256
4	Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. European Heart Journal, 2004, 25, 523-530.	2.2	89
5	The natriuretic peptides in cardiovascular medicine. Current Problems in Cardiology, 2004, 29, 707-769.	2.4	131
6	Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. American Journal of Cardiology, 2004, 93, 234-237.	1.6	74
7	Phosphinic peptides as zinc metalloproteinase inhibitors. Cellular and Molecular Life Sciences, 2004, 61, 2010-9.	5.4	86
8	Risk factors for heart failure. Medical Clinics of North America, 2004, 88, 1145-1172.	2.5	92
9	Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. Journal of the American College of Cardiology, 2004, 44, 878-886.	2.8	537
10	Extended follow-up of patients randomly assigned in the angiotensin-converting enzyme inhibition post-revascularization study (APRES). American Heart Journal, 2004, 148, 475-480.	2.7	11
11	The Emerging Role of Echocardiography in the Screening of Patients at Risk of Heart Failure. American Journal of Cardiology, 2005, 96, 42-51.	1.6	52
13	Comparative sensitivities betweendifferent plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone, 2005, 7, S18-S24.	0.7	11
14	Systolic time intervals revisited: correlations with N-terminal pro-brain natriuretic peptide in a community population. Heart and Vessels, 2005, 20, 256-263.	1.2	16
15	Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension. Hypertension, 2005, 45, 412-418.	2.7	58
16	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	2.2	1,986
17	Miocardiopat?as: concepto, clasificaci?n. Miocardiopat?a dilatada idiop?tica. Medicine, 2005, 9, 2765-2774.	0.0	O
18	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitor Therapy. Heart Failure Clinics, 2005, 1, 25-37.	2.1	0
19	Natriuretic Peptides and Remodeling in Heart Failure. Heart Failure Clinics, 2005, 1, 129-139.	2.1	5

#	Article	IF	CITATIONS
21	The heart failure challenge: Optimizing medical and surgical management. Canadian Journal of Cardiology, 2006, 22, 8C-12C.	1.7	2
22	Natriuretic Peptides in Screening for Cardiac Dysfunction. Heart Failure Clinics, 2006, 2, 323-332.	2.1	1
23	Analysis of Regional Left Ventricular Function by Cineventriculography, Cardiac Magnetic Resonance Imaging, and Unenhanced and Contrast-Enhanced Echocardiography. Journal of the American College of Cardiology, 2006, 47, 121-128.	2.8	155
24	Left Ventricular Systolic Dysfunction in Rheumatoid Disease. Journal of the American College of Cardiology, 2006, 47, 1169-1174.	2.8	50
25	Prognostic Value of Pacing-Induced Mechanical Alternans in Patients With Mild-to-Moderate Idiopathic Dilated Cardiomyopathy in Sinus Rhythm. Journal of the American College of Cardiology, 2006, 47, 1382-1389.	2.8	26
26	Subclinical Atherosclerosis and Incipient Regional Myocardial Dysfunction in Asymptomatic Individuals. Journal of the American College of Cardiology, 2006, 47, 2420-2428.	2.8	93
28	Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study. Journal of Cardiac Failure, 2006, 12, 601-607.	1.7	68
29	Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failureâ€"the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. American Heart Journal, 2006, 151, 288-294.	2.7	85
30	Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sciences, 2006, 79, 1600-1605.	4.3	17
31	Progression of heart failure in right univentricular pacing compared to biventricular pacing. International Journal of Cardiology, 2006, 110, 359-365.	1.7	11
32	Frontmattre., 0,, i-xiii.		0
33	Left Ventricular Systolic Dysfunction and the Risk of Ischemic Stroke in a Multiethnic Population. Stroke, 2006, 37, 1715-1719.	2.0	143
34	Elevated Levels of Oxidative DNA Damage in Serum and Myocardium of Patients With Heart Failure. Circulation Journal, 2006, 70, 1001-1005.	1.6	90
35	Atherosclerosis imaging and heart failure. Heart Failure Reviews, 2006, 11, 279-288.	3.9	6
36	Screening for ventricular remodeling. Current Heart Failure Reports, 2006, 3, 5-13.	3.3	7
37	Contrast-enhanced echocardiography improves agreement on the assessment of ejection fraction and left ventricular function. A multicentre study. European Journal of Echocardiography, 2006, 7, S16-S21.	2.3	1
38	What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?. European Heart Journal, 2006, 27, 193-200.	2.2	80
39	Managing the Post-Myocardial Infarction Patient with Asymptomatic Left Ventricular Dysfunction. Cardiology, 2006, 105, 95-107.	1.4	6

#	ARTICLE	IF	CITATIONS
40	Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. European Heart Journal, 2006, 27, 1868-1875.	2.2	142
41	Stage B Heart Failure. Circulation, 2006, 113, 2851-2860.	1.6	135
43	Women Have Higher Left Ventricular Ejection Fractions Than Men Independent of Differences in Left Ventricular Volume. Circulation, 2006, 113, 1597-1604.	1.6	205
44	Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. Journal of the American Society of Nephrology: JASN, 2006, 17, 1460-1465.	6.1	48
46	Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction. Hypertension, 2007, 50, 481-488.	2.7	7
47	Prevalence and Prognostic Significance of Heart Failure Stages. Circulation, 2007, 115, 1563-1570.	1.6	416
48	Elevated Homocysteine Is Associated With Reduced Regional Left Ventricular Function. Circulation, 2007, 115, 180-187.	1.6	53
49	Risk Factors for Development of Heart Failure. Current Cardiology Reviews, 2007, 3, 1-9.	1.5	1
50	Long-Term Survival of Incident Hemodialysis Patients Who Are Hospitalized for Congestive Heart Failure, Pulmonary Edema, or Fluid Overload. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1186-1190.	4. 5	77
51	Feasibility and clinical decision-making with 3D echocardiography in routine practice. Heart, 2007, 94, 440-445.	2.9	57
52	Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction. Circulation, 2007, 116, 49-56.	1.6	156
53	CD36 Expression Contributes to Age-Induced Cardiomyopathy in Mice. Circulation, 2007, 116, 2139-2147.	1.6	114
55	Quantitative left ventricular systolic function: From chamber to myocardium. Critical Care Medicine, 2007, 35, S330-S339.	0.9	47
56	Regional left ventricular function in individuals with mild to moderate renal insufficiency: The Multi-Ethnic Study of Atherosclerosis. American Heart Journal, 2007, 153, 545-551.	2.7	27
57	Clinical epidemiology of heart failure. Heart, 2007, 93, 1137-1146.	2.9	1,448
58	Quantification of Left Ventricular Volumes and Function in Patients with Cardiomyopathies by Real-time Three-dimensional Echocardiography: A Head-to-Head Comparison Between Two Different Semiautomated Endocardial Border Detection Algorithms. Journal of the American Society of Echocardiography, 2007, 20, 1042-1049.	2.8	61
59	Models of cardiac hypertrophy and transition to heart failure. Drug Discovery Today: Disease Models, 2007, 4, 197-206.	1.2	15
60	Cardiac autophagy is a maladaptive response to hemodynamic stress. Journal of Clinical Investigation, 2007, 117, 1782-1793.	8.2	672

#	Article	IF	CITATIONS
61	How Many Planes Are Required to Get an Accurate and Timesaving Measurement of Left Ventricular Volume and Function by Real-Time Three-Dimensional Echocardiography in Acute Myocardial Infarction?. Ultrasound in Medicine and Biology, 2007, 33, 1572-1578.	1.5	5
62	A Comparison between QLAB and TomTec Full Volume Reconstruction for Real Time Three-Dimensional Echocardiographic Quantification of Left Ventricular Volumes. Echocardiography, 2007, 24, 967-974.	0.9	87
63	Comparison of Two- and Three-Dimensional Echocardiography With Sequential Magnetic Resonance Imaging for Evaluating Left Ventricular Volume and Ejection Fraction Over Time in Patients With Healed Myocardial Infarction. American Journal of Cardiology, 2007, 99, 300-306.	1.6	163
64	Comparison of the Frequency of Abnormal Cardiac Findings by Echocardiography in Patients With and Without Peripheral Arterial Disease. American Journal of Cardiology, 2007, 99, 499-503.	1.6	21
65	Left Ventricular Dysfunction and Mortality in Adult Patients with Eisenmenger Syndrome. Congenital Heart Disease, 2007, 2, 156-164.	0.2	8
66	Gated SPECT: What's the ideal method to measure LVEF?. International Journal of Cardiovascular Imaging, 2008, 24, 807-810.	1.5	4
67	Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 476-485.	0.9	2
68	Force for the Diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal,	2.2	2,656
69	Risk Factors for Ischaemic Stroke. International Journal of Stroke, 2008, 3, 105-116.	5.9	156
70	Comparison of Magnetic Resonance Imaging and Transthoracic Echocardiography for the Identification of LV Mass and Volume Regression Indices 6 months after Mitral Valve Repair. Journal of Cardiac Surgery, 2008, 23, 126-132.	0.7	11
71	Performance of Conventional Echocardiographic Parameters and Myocardial Measurements in the Sequential Evaluation of Left Ventricular Function. American Journal of Cardiology, 2008, 101, 706-711.	1.6	36
72	Device Therapies in the Post-Myocardial Infarction Patient with Left Ventricular Dysfunction. American Journal of Cardiology, 2008, 102, 29G-37G.	1.6	5
73	Detection of Regional Myocardial Dysfunction in Patients with Acute Myocardial Infarction Using Velocity Vector Imaging. Journal of the American Society of Echocardiography, 2008, 21, 879-886.	2.8	58
74	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. Cardiology Clinics, 2008, 26, 1-14.	2.2	20
75	Blacks and whites have a similar prevalence of reduced left ventricular ejection fraction in the general population: The Dallas Heart Study (DHS). American Heart Journal, 2008, 155, 876-882.	2.7	7
76	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
77	GuÃa de práctica clÃnica de la Sociedad Europea de CardiologÃa (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Espanola De Cardiologia, 2008, 61, 1329.e1-1329.e70.	1.2	36
78	Heart Failure: Who We Treat Versus Who We Study. Cardiology Clinics, 2008, 26, 113-125.	2.2	14

#	Article	IF	Citations
79	Arterial Hypertension and Cardiac Damage. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 141-170.	2.2	10
80	Predominance of Heart Failure in the Heart of Soweto Study Cohort. Circulation, 2008, 118, 2360-2367.	1.6	168
81	Prognostic impact of NTâ€proBNP and renal function in comparison to contemporary multiâ€marker risk scores in heart failure patients. European Journal of Heart Failure, 2008, 10, 315-320.	7.1	56
82	Arterial Stiffness Is Associated With Regional Ventricular Systolic and Diastolic Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 194-201.	2.4	100
83	Chronic heart failure, selected risk factors and coâ€morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. European Journal of Heart Failure, 2008, 10, 367-372.	7.1	32
84	Prevention of Heart Failure. Circulation, 2008, 117, 2544-2565.	1.6	485
85	Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax, 2008, 63, 487-492.	5.6	232
86	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. Cardiology, 2008, 110, 271-282.	1.4	39
87	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡. European Journal of Heart Failure, 2008, 10, 933-989.	7.1	1,893
88	Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial. Yearbook of Medicine, 2008, 2008, 394-395.	0.1	0
89	Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. Yearbook of Medicine, 2008, 2008, 395-398.	0.1	0
90	Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial. Yearbook of Cardiology, 2008, 2008, 374-375.	0.0	0
91	Right Bundle Branch Block and Impaired Left Ventricular Function as Evidence of a Left Ventricular Conduction Delay. Circulation Journal, 2008, 72, 120-126.	1.6	19
92	Development of heart failure in recent hypertension trials. Journal of Hypertension, 2008, 26, 1477-1486.	0.5	105
93	Cardiac remodelling and dysfunction in children with obstructive sleep apnoea: a community based study. Thorax, 2009, 64, 233-239.	5.6	65
94	Risk stratification by T-wave morphology for cardiovascular mortality in patients with systolic heart failure. Europace, 2009, 11, 1522-1528.	1.7	18
95	Genetic Variants Associated With Cardiac Structure and Function. JAMA - Journal of the American Medical Association, 2009, 302, 168.	7.4	202
96	MADIT-CRT â€" Breathtaking or Time to Catch Our Breath?. New England Journal of Medicine, 2009, 361, 1394-1396.	27.0	17

#	ARTICLE	IF	CITATIONS
97	Functional measurements based on feature tracking of cine magnetic resonance images identify left ventricular segments with myocardial scar. Cardiovascular Ultrasound, 2009, 7, 53.	1.6	115
98	Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Internal Medicine Journal, 2009, 39, 812-818.	0.8	41
99	Plasma Nâ€Terminal Protypeâ€B Natriuretic Peptide and Restrictive Mitral Flow to Riskâ€stratify Patients with Stage B Heart Failure. Clinical Cardiology, 2009, 32, 711-717.	1.8	5
100	Echocardiographic parameters and all-cause mortality: The Rotterdam Study. International Journal of Cardiology, 2009, 133, 198-204.	1.7	40
101	Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study. American Heart Journal, 2009, 157, 746-753.e2.	2.7	85
104	Can NT-proBNP predict risk of cardiovascular mortality within 10Âyears? Results from an epidemiological study of elderly patients with symptoms of heart failure. International Journal of Cardiology, 2009, 133, 233-240.	1.7	11
105	Heart failure. Lancet, The, 2009, 373, 941-955.	13.7	152
106	Natriuretic Peptides in the Diagnosis and Management of Chronic Heart Failure. Heart Failure Clinics, 2009, 5, 501-514.	2.1	53
107	Î ² -Blocker Use for the Stages of Heart Failure. Mayo Clinic Proceedings, 2009, 84, 718-729.	3.0	74
108	Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients. Journal of Cardiovascular Medicine, 2009, 10, 238-244.	1.5	4
110	Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure $\hat{a} \in \hat{a}$ a subgroup analysis from the Trieste Cardiomyopathy Registry. Journal of Cardiovascular Medicine, 2009, 10, 699-705.	1.5	41
111	Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. Journal of Applied Genetics, 2010, 51, 353-368.	1.9	15
112	Cardiac Resynchronization Therapy in Mild Heart Failure: A Review of the REVERSE and MADIT-CRT Trials. Current Cardiology Reports, 2010, 12, 367-373.	2.9	10
113	Distribution of echocardiographic parameters and their associations with cardiovascular risk factors in the Rotterdam Study. European Journal of Epidemiology, 2010, 25, 481-490.	5.7	21
114	Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: A prospective followâ€up study. Pediatric Blood and Cancer, 2010, 54, 579-584.	1.5	18
115	Aortic Root Dimension as an Independent Predictor for Allâ€Cause Death in Adults <65 Years of Age (from The Chinâ€Shan Community Cardiovascular Cohort Study). Echocardiography, 2010, 27, 487-495.	0.9	26
116	Left Ventricle and Left Atrium Remodeling after Mitral Valve Replacement in Case of Mixed Mitral Valve Disease of Rheumatic Origin. Journal of Cardiac Surgery, 2010, 25, 367-372.	0.7	7
117	Long-Term Anabolic-Androgenic Steroid Use Is Associated With Left Ventricular Dysfunction. Circulation: Heart Failure, 2010, 3, 472-476.	3.9	149

#	Article	IF	CITATIONS
118	Prognostic impact of familial screening in dilated cardiomyopathy. European Journal of Heart Failure, 2010, 12, 922-927.	7.1	51
119	Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: systematic review and metaâ€analysis of randomized trials. European Journal of Heart Failure, 2010, 12, 360-366.	7.1	36
120	Cardiac Magnetic Resonance Imaging as a Prognostic Tool in Patients with Nonischemic Cardiomyopathy. Hospital Practice (1995), 2010, 38, 75-82.	1.0	2
121	ABCD's of Heart Failure: Echo-ing through the First Stage. Journal of the American Society of Echocardiography, 2010, 23, 1035-1038.	2.8	1
123	Assessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers for the Prediction of Incident Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 56, 1712-1719.	2.8	273
124	Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. Journal of the American College of Cardiology, 2010, 56, 1644-1650.	2.8	125
125	Screening for Left Ventricular Systolic Dysfunction: Is Imaging a Solution?. JACC: Cardiovascular Imaging, 2010, 3, 421-428.	5.3	39
126	Prediction of ACC/AHA Stage B Heart Failure by Clinical and Neurohormonal Profiling Among Patients in the Community. Journal of Cardiac Failure, 2010, 16, 957-963.	1.7	3
127	Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans. American Heart Journal, 2010, 160, 488-495.	2.7	8
128	The Incremental Prognostic Value of Echocardiography in Asymptomatic Stage A Heart Failure. Journal of the American Society of Echocardiography, 2010, 23, 1025-1034.	2.8	34
129	The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure. Journal of Rheumatology, 2011, 38, 1601-1606.	2.0	94
130	The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays. Mayo Clinic Proceedings, 2011, 86, 210-218.	3.0	21
131	Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemotherapy: Is It Time to Change Tracks?. Heart Failure Clinics, 2011, 7, xiii-xix.	2.1	4
132	The Early Intertwining of the Heart and the Kidney Through an Impaired Natriuretic Response to Acute Volume Expansion. Journal of the American College of Cardiology, 2011, 58, 2104-2105.	2.8	6
133	Left Ventricular Ejection Fraction Assessment in Older Adults. Journal of the American College of Cardiology, 2011, 58, 1497-1506.	2.8	22
134	Impaired Natriuretic and Renal Endocrine Response to Acute Volume Expansion in Pre-Clinical Systolic and Diastolic Dysfunction. Journal of the American College of Cardiology, 2011, 58, 2095-2103.	2.8	70
135	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
136	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .		7

#	ARTICLE	IF	CITATIONS
137	Feasibility of Single-Beat Full-Volume Capture Real-Time Three-Dimensional Echocardiography and Auto-Contouring Algorithm for Quantification of Left Ventricular Volume: Validation with Cardiac Magnetic Resonance Imaging. Journal of the American Society of Echocardiography, 2011, 24, 853-859.	2.8	65
138	The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung and Circulation, 2011, 20, 3-9.	0.4	18
139	Detection of left ventricular systolic dysfunction using a newly developed, laptop based, impedance cardiographic index. International Journal of Cardiology, 2011, 149, 248-250.	1.7	7
140	Signs for early diagnosis of heart failure in primary health care. Vascular Health and Risk Management, 2011, 7, 591.	2.3	9
141	Epidemiology of Heart Failure. , 2011, , 346-354.		0
142	The Prognostic Value of Non-Linear Analysis of Heart Rate Variability in Patients with Congestive Heart Failureâ€"A Pilot Study of Multiscale Entropy. PLoS ONE, 2011, 6, e18699.	2.5	87
143	In search of the best prognostic factor in patients with congestive heart failure: the paradox of ejection fraction without prognostic significance. Journal of Cardiovascular Medicine, 2011, 12, 314-317.	1.5	4
144	Comparative values of gated blood-pool SPECT and CMR for ejection fraction and volume estimation. Nuclear Medicine Communications, 2011, 32, 121-128.	1.1	29
145	Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. , 2011, , CD008011.		23
146	Cumulative Impact of Cardiovascular Risk Factors on Regional Left Ventricular Function and Reserve: Progressive Long-Axis Dysfunction with Compensatory Radial Changes. Echocardiography, 2011, 28, 813-820.	0.9	14
147	Current Perspectives on Diagnosis of Heart Failure in Long-term Dialysis Patients. American Journal of Kidney Diseases, 2011, 57, 308-319.	1.9	30
148	Left Ventricular Function Assessed by Two-Dimensional Speckle Tracking Echocardiography in Long-Term Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy With or Without Anthracycline Therapy. American Journal of Cardiology, 2011, 107, 472-477.	1.6	95
149	Comparison of Characteristics and Outcomes of Asymptomatic Versus Symptomatic Left Ventricular Dysfunction in Subjects 65 Years Old or Older (from the Cardiovascular Health Study). American Journal of Cardiology, 2011, 107, 1667-1674.	1.6	21
150	Influence of CT-based attenuation correction in assessment of left and right ventricular functions with count-based gated blood-pool SPECT. Journal of Nuclear Cardiology, 2011, 18, 642-649.	2.1	7
151	Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community. Circulation, 2011, 124, 24-30.	1.6	274
152	Left Ventricular Assist Devices Are Underutilized. Circulation, 2011, 123, 1552-1558.	1.6	92
153	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 415-423.	2.8	28
155	Cardiac Function in 5-Year Survivors of Childhood Cancer. Archives of Internal Medicine, 2011, 171, 264.	3.8	1

#	ARTICLE	IF	Citations
156	Cardiac Function in 5-Year Survivors of Childhood Cancerâ€"Reply. Archives of Internal Medicine, 2011, 171, 264.	3.8	1
157	Aging, Blood Pressure, and Heart Failure. Hypertension, 2011, 58, 760-762.	2.7	13
158	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. Scientifica, 2012, 2012, 1-16.	1.7	7
159	The Natural History of Preclinical Diastolic Dysfunction. Circulation: Heart Failure, 2012, 5, 144-151.	3.9	84
160	Prevalence of preclinical and clinical heart failure in the elderly. A populationâ€based study in Central Italy. European Journal of Heart Failure, 2012, 14, 718-729.	7.1	92
161	The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of Oncology, 2012, 23, 2191-2198.	1.2	47
162	Prognosis of Individuals With Asymptomatic Left Ventricular Systolic Dysfunction in the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2012, 126, 2713-2719.	1.6	90
164	Running on Empty: Cardiovascular Reserve Capacity and Late Effects of Therapy in Cancer Survivorship. Journal of Clinical Oncology, 2012, 30, 4458-4461.	1.6	63
165	Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3515-3521.	3.6	58
166	Advanced echocardiographic techniques. Australasian Journal of Ultrasound in Medicine, 2012, 15, 126-142.	0.6	0
167	Radionuclide Imaging in Stage B Heart Failure. Heart Failure Clinics, 2012, 8, 191-206.	2.1	5
168	Cardiac Magnetic Resonance Imaging for Stage B Heart Failure. Heart Failure Clinics, 2012, 8, 179-190.	2.1	10
169	Clinical Monitoring of Stage B Heart Failure: Echocardiography. Heart Failure Clinics, 2012, 8, 169-178.	2.1	7
170	Cochrane Review: Medical interventions for treating anthracyclineâ€induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 1857-1902.	2.0	1
171	Sources of variation and bias in assessing left ventricular volumes and dyssynchrony using three-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2012, 28, 1357-1368.	1.5	28
172	Assessment of left ventricular systolic function by velocity vector imaging. Indian Heart Journal, 2012, 64, 146-149.	0.5	6
173	Cardiopatia ipertensiva e insufficienza cardiaca con normale frazione di eiezione ventricolare sinistra. Ruolo dell'ecocardiografia convenzionale e di quella avanzata nella valutazione della disfunzione ventricolare sinistra. Journal of Cardiovascular Echography, 2012, 22, 74-90.	0.4	0
174	Strategies to Screen for Stage B as a Heart Failure Prevention Intervention. Heart Failure Clinics, 2012, 8, 285-296.	2.1	6

#	Article	IF	CITATIONS
175	Stage B Heart Failure: Rationale for Screening. Heart Failure Clinics, 2012, 8, 273-283.	2.1	12
176	Asymptomatic systolic and diastolic dysfunction in patients with risk factors referred for echocardiography. The DAVES study by the Italian Society of Cardiovascular Echography. Journal of Cardiovascular Echography, 2012, 22, 29-36.	0.4	0
177	Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation: Cardiovascular Imaging, 2012, 5, 596-603.	2.6	653
178	Association of number of live births with left ventricular structure and function. The Multi-Ethnic Study of Atherosclerosis (MESA). American Heart Journal, 2012, 163, 470-476.	2.7	22
179	Inverted mitral inflow pattern in echocardiography among the elderly â€" A marker of non-cardiovascular mortality and cognitive dysfunction. International Journal of Cardiology, 2012, 155, 70-74.	1.7	3
180	Heart Failure in Hypertension. Drugs, 2012, 72, 1373-1398.	10.9	16
181	The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: Implications for timing of implantable cardioverter-defibrillator implantation. American Heart Journal, 2012, 164, 358-364.	2.7	38
182	The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older. Peptides, 2012, 38, 118-126.	2.4	9
183	Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography. Current Cardiovascular Imaging Reports, 2012, 5, 403-409.	0.6	31
184	Integrating Optimal Use of Echocardiography and Biomarkers in Heart Disease. Current Cardiovascular Imaging Reports, 2012, 5, 444-451.	0.6	0
185	Reducing the Burden of Stage B Heart Failure Will Require Connecting the Dots Between "Knowns― and "Known Unknowns― Heart Failure Clinics, 2012, 8, xi-xv.	2.1	1
186	Echocardiographic Serial Changes of Hypertensive Cardiomyopathy With Severely Reduced Ejection Fraction: Comparison With Idiopathic Dilated Cardiomyopathy. Clinical Cardiology, 2012, 35, 554-558.	1.8	1
187	Left-Ventricular Function Quantitative Parameters and Their Relationship to Acute Loading Variation: From Physiology to Clinical Practice. Current Cardiovascular Imaging Reports, 2012, 5, 83-91.	0.6	0
188	Diagnostic Utility and Clinical Usefulness of the Pocket Echocardiographic Device. Echocardiography, 2012, 29, 1-6.	0.9	29
189	Cardiac Structure and Function as Predictors of Mortality in Persons 85 Years of Age. American Journal of Cardiology, 2012, 109, 901-905.	1.6	15
190	Hyperuricemia and the Echocardiographic Measures of Myocardial Dysfunction. Congestive Heart Failure, 2012, 18, 138-143.	2.0	30
191	Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction. Cardiovascular Ultrasound, 2013, 11, 19.	1.6	15
192	Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nature Reviews Cardiology, 2013, 10, 531-547.	13.7	763

#	Article	IF	CITATIONS
193	Intermittent-hypoxia induced autophagy attenuates contractile dysfunction and myocardial injury in rat heart. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1159-1166.	3.8	55
194	Asymptomatic Cardiac Toxicity in Long-Term Cancer Survivors: Defining the Population and Recommendations for Surveillance. Seminars in Oncology, 2013, 40, 229-238.	2.2	50
195	Evaluation of automated measurement of left ventricular volume by novel real-time 3-dimensional echocardiographic system: Validation with cardiac magnetic resonance imaging and 2-dimensional echocardiography. Journal of Cardiology, 2013, 61, 281-288.	1.9	29
196	Preventing Heart Failure: A Critique of Strategies. Journal of Cardiac Failure, 2013, 19, 211-213.	1.7	2
197	Novel single-beat full-volume capture real-time three-dimensional echocardiography and auto-contouring algorithm for quantification of left ventricular volume: Validation with cardiac magnetic resonance imaging. International Journal of Cardiology, 2013, 168, 2946-2948.	1.7	16
198	Natriuretic peptides and the Framingham Risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. International Journal of Cardiology, 2013, 168, 5093-5095.	1.7	7
199	Value of Adding Natriuretic Peptides and Electrocardiographic Findings to Assess the Presence of Cardiac Dysfunction in Patients ≥80 Years of Age. American Journal of Cardiology, 2013, 111, 1198-1208.	1.6	4
200	Biomarkers and diagnostics in heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2442-2450.	3.8	298
201	Early Identification of Asymptomatic Subjects at Increased Risk of Heart Failure and Cardiovascular Events: Progress and Future Directions. Heart Lung and Circulation, 2013, 22, 171-178.	0.4	7
202	Prevalence of Asymptomatic Left Ventricular Systolic Dysfunction in At-risk Medical Inpatients. American Journal of Medicine, 2013, 126, 68-73.	1.5	9
203	Abnormal electrocardiographic findings in athletes: recognising changes suggestive of cardiomyopathy. British Journal of Sports Medicine, 2013, 47, 137-152.	6.7	121
204	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 2013, 34, 2263-2270.	2.2	85
205	Cardiovascular Management of Cancer Patients With Chemotherapy-Associated Left Ventricular Systolic Dysfunction in Real-World Clinical Practice. Journal of Cardiac Failure, 2013, 19, 629-634.	1.7	39
206	Left atrial structure and function and clinical outcomes in the general population. European Heart Journal, 2013, 34, 278-285.	2.2	188
207	Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E243-E253.	3.5	105
208	Electrocardiographic Findings Suggestive of Cardiomyopathy. Current Sports Medicine Reports, 2013, 12, 77-85.	1.2	11
209	Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart, 2013, 99, 634-639.	2.9	89
210	Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics, 2013, 14, 205-213.	1.3	35

#	Article	IF	CITATIONS
211	Diagnosis and Treatment of Asymptomatic Left Ventricular Systolic Dysfunction after Myocardial Infarction. ISRN Cardiology, 2013, 2013, 1-7.	1.6	4
212	Prognostic Importance of a New Measure of Global Systolic Heart Function in Healthy Adults. Hypertension, 2013, 61, 762-764.	2.7	3
213	Should we screen for heart failure in the elderly?. European Journal of Heart Failure, 2013, 15, 125-127.	7.1	2
214	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‣Y trial. European Journal of Heart Failure, 2013, 15, 1053-1061.	7.1	82
215	Prognostic value of myocardial circumferential strain for incident heart failure and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. European Heart Journal, 2013, 34, 2354-2361.	2.2	126
216	Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International, 2014, 2014, 1-21.	1.9	107
217	Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?. Current Cardiology Reviews, 2014, 11, 18-22.	1.5	12
218	Utility of NT-proBNP as a rule-out test for left ventricular dysfunction in very old people with limiting dyspnoea: the Newcastle 85+ Study. BMC Cardiovascular Disorders, 2014, 14, 128.	1.7	8
219	Left ventricular systolic dysfunction inÂoutpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease. European Journal of Heart Failure, 2014, 16, 625-632.	7.1	26
220	Chemotherapyâ€related cardiomyopathy: a neglected aspect of cancer survivorship. Internal Medicine Journal, 2014, 44, 939-950.	0.8	19
221	Left Ventricular Dilation and Incident Congestive Heart Failure in Asymptomatic Adults Without Cardiovascular Disease: Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Cardiac Failure, 2014, 20, 905-911.	1.7	42
222	The middle child in heart failure: heart failure with midâ€range ejection fraction (40–50%). European Journal of Heart Failure, 2014, 16, 1049-1055.	7.1	172
223	Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a communityâ€based cohort. European Journal of Heart Failure, 2014, 16, 1301-1309.	7.1	195
224	Pulmonary fluid overload monitoring in heart failure patients with single and dual chamber defibrillators. Journal of Cardiovascular Medicine, 2014, 15, 307-314.	1.5	4
225	Relation of Left Ventricular Mass at Age 23 to 35 Years to Global Left Ventricular Systolic Function 20 Years Later (from the Coronary Artery Risk Development in Young Adults Study). American Journal of Cardiology, 2014, 113, 377-383.	1.6	16
226	Single-beat real-time three-dimensional echocardiographic automated contour detection for quantification of left ventricular volumes and systolic function. International Journal of Cardiovascular Imaging, 2014, 30, 287-294.	1.5	6
228	The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet, The, 2014, 383, 999-1008.	13.7	1,024
229	Management of ACCF/AHA Stage A and B Patients. Cardiology Clinics, 2014, 32, 63-71.	2.2	6

#	Article	IF	Citations
230	The relationship between physical performance and cardiac function in an elderly Russian cohort. Archives of Gerontology and Geriatrics, 2014, 59, 554-561.	3.0	4
231	Incremental Prognostic Value of Myocardial Fibrosis in Patients With Non–Ischemic Cardiomyopathy Without Congestive Heart Failure. Circulation: Heart Failure, 2014, 7, 448-456.	3.9	94
232	Characteristics of Trabeculated Myocardium Burden in Young and Apparently Healthy Adults. American Journal of Cardiology, 2014, 114, 1094-1099.	1.6	22
233	What Is Normal in HFNEF?. JACC: Heart Failure, 2014, 2, 541-543.	4.1	5
234	Prevalence and Clinical Correlation of Left Ventricular Systolic Dysfunction in African Americans with Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 1965-1968.	1.6	2
235	Association of Cardiorespiratory Fitness With Left Ventricular Remodeling and Diastolic Function. JACC: Heart Failure, 2014, 2, 238-246.	4.1	81
236	Association of Outcome with Left Ventricular Parameters Measured by Two-Dimensional and Three-Dimensional Echocardiography in Patients at High Cardiovascular Risk. Journal of the American Society of Echocardiography, 2014, 27, 65-73.	2.8	33
237	Cardiac Target Organ Damage in Hypertension: Insights from Epidemiology. Current Hypertension Reports, 2014, 16, 446.	3. 5	8
238	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	2.2	71
239	Amiodarone-Induced Thyrotoxicosis. , 2014, , 127-135.		O
240	Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical and Economic Effects. Annals of Internal Medicine, 2014, 160, 661.	3.9	83
241	Cardiovascular and Mortality Outcomes in the Elderly With Impaired Cardiac and Pulmonary Function: The Cardiovascular Health Study (CHS). Journal of the American Heart Association, 2015, 4, .	3.7	7
242	Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. International Journal of Epidemiology, 2015, 44, 1800-1813.	1.9	269
243	Distinct Aspects of Left Ventricular Mechanical Function Are Differentially Associated With Cardiovascular Outcomes and All ause Mortality in the Community. Journal of the American Heart Association, 2015, 4, e002071.	3.7	58
244	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. American Heart Journal, 2015, 169, 257-265.e1.	2.7	33
245	Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication $\hat{a} \in \text{``results from the CAVASIC Study. Atherosclerosis, 2015, 239, 428-435.}$	0.8	12
246	Role of electrocardiography and echocardiography in prevention and predicting outcome of subjects at increased risk of heart failure. European Journal of Preventive Cardiology, 2015, 22, 249-262.	1.8	11
247	Subclinical cardiac dysfunction increases the risk of stroke and dementia. Neurology, 2015, 84, 833-840.	1.1	42

#	ARTICLE	IF	CITATIONS
248	Caring for the Cardio-Oncology Patient: Straining to Foresee the Future. Journal of the American Society of Echocardiography, 2015, 28, 515-516.	2.8	2
249	Race-ethnic differences in subclinical left ventricular systolic dysfunction by global longitudinal strain: A community-based cohort study. American Heart Journal, 2015, 169, 721-726.	2.7	12
250	Clinical prediction of incident heart failure risk: a systematic review and meta-analysis. Open Heart, 2015, 2, e000222.	2.3	73
251	Cardioprotective role of \hat{l}^2 -blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal, 2015, 91, 627-633.	1.8	42
252	Heart Failure in Women $\hat{a}\in$ Insights from the Framingham Heart Study. Cardiovascular Drugs and Therapy, 2015, 29, 377-390.	2.6	54
253	Cardiometabolic Disease Leading to Heart Failure: Better Fat and Fit Than Lean and Lazy. Current Heart Failure Reports, 2015, 12, 302-308.	3.3	34
254	Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study. Journal of Clinical Oncology, 2015, 33, 2683-2691.	1.6	44
255	Baroreflex activation therapy for the treatment of heart failure. Interventional Cardiology, 2015, 7, 559-569.	0.0	1
256	Exercise Limitation Associated With Asymptomatic Left Ventricular Impairment. Journal of the American College of Cardiology, 2015, 65, 257-266.	2.8	60
258	A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-7.	4.0	17
259	Prediction of atrial fibrillation development and progression: Current perspectives. World Journal of Cardiology, 2016, 8, 267.	1.5	44
260	Chaos Based Quantitative Risk Assessment of Cardiac Dysfunction. Chemical Informatics (Wilmington,) Tj ETQq1	1.0,78431 0.4	4 rgBT /Ov
261	Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy. Annals of Internal Medicine, 2016, 164, 93.	3.9	169
262	Prevalence, Incidence and Lifetime Risk of Heart Failure. , 2016, , 3-13.		1
264	Atrial Fibrillation in Heart Failure. Circulation, 2016, 133, 1631-1633.	1.6	3
265	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	2.2	13,008
266	Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter–Defibrillator Therapy. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	54
267	ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Failure, 2016, 3, 44-52.	3.1	23

#	Article	IF	Citations
268	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	7.1	5,272
269	Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. The Cochrane Library, 2016, 2016, CD008011.	2.8	34
270	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. International Journal of Cardiology, 2016, 224, 366-375.	1.7	32
271	Contrast-Specific Imaging Without Contrast. JACC: Cardiovascular Imaging, 2016, 9, 1252-1254.	5.3	2
272	Response to Letter Regarding Article, "Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction― Circulation, 2016, 133, e692-3.	1.6	45
273	Routine Prophylactic Cardioprotective Therapy Should Be Given to All Recipients at Risk of Cardiotoxicity From Cancer Chemotherapy. Canadian Journal of Cardiology, 2016, 32, 921-925.	1.7	7
274	Left Ventricular Ejection Fraction. JACC: Heart Failure, 2016, 4, 511-513.	4.1	15
275	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. JACC: Heart Failure, 2016, 4, 502-510.	4.1	49
276	Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. Oncologist, 2016, 21, 141-149.	3.7	28
277	Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. European Journal of Heart Failure, 2016, 18, 433-441.	7.1	22
278	Red cell distribution width (RDW) correlates with markers of diastolic dysfunction in patients with impaired left ventricular systolic function. IJC Heart and Vasculature, 2016, 10, 13-16.	1.1	4
279	Asymptomatic Left Ventricular Dysfunction. JACC: Heart Failure, 2016, 4, 249-251.	4.1	9
280	Subclinical Abnormalities in Echocardiographic Parameters and Risk of Sudden Cardiac Death in a General Population: The Rotterdam Study. Journal of Cardiac Failure, 2016, 22, 17-23.	1.7	8
281	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. Journal of Clinical Oncology, 2016, 34, 1030-1033.	1.6	82
282	Atrial Fibrillation Begets Heart Failure and Vice Versa. Circulation, 2016, 133, 484-492.	1.6	561
283	Assessing the Risk of Progression FromÂAsymptomatic Left Ventricular Dysfunction to Overt Heart Failure. JACC: Heart Failure, 2016, 4, 237-248.	4.1	94
284	Subclinical pulmonary congestion is prevalent in nephrotic syndrome. Kidney International, 2016, 89, 421-428.	5.2	21
285	Utility of Normal Findings on Electrocardiogram and Echocardiogram in Subjects ≥65ÂYears. American Journal of Cardiology, 2017, 119, 856-861.	1.6	2

#	Article	IF	CITATIONS
286	Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 371-376.	0.9	33
287	Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors. Heart Failure Clinics, 2017, 13, 337-345.	2.1	10
288	Cardio-Oncology. , 2017, , .		1
289	Serial heart rhythm complexity changes in patients with anterior wall ST segment elevation myocardial infarction. Scientific Reports, 2017, 7, 43507.	3.3	15
290	Characteristics and Course of Heart Failure Stages A–B and Determinants of Progression – design and rationale of the STAAB cohort study. European Journal of Preventive Cardiology, 2017, 24, 468-479.	1.8	30
291	Cardiac Toxic Chemotherapy and Cancer Survivorship., 2017,, 253-280.		0
292	Visibility graph analysis of heart rate time series and bio-marker of congestive heart failure. Physica A: Statistical Mechanics and Its Applications, 2017, 482, 786-795.	2.6	18
293	Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer. Journal of Clinical Ultrasound, 2017, 45, 222-230.	0.8	22
294	Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients. Journal of the American Society of Hypertension, 2017, 11, 412-419.	2.3	18
295	8-Hydroxy-2-deoxyguanosine levels and heart failure: A systematic review and meta-analysis of the literature. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 201-208.	2.6	38
296	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Advances in Experimental Medicine and Biology, 2017, 1067, 197-217.	1.6	44
297	Heart Failure With Mid-Range (Borderline) Ejection Fraction. JACC: Heart Failure, 2017, 5, 763-771.	4.1	141
298	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	1.7	503
300	Relationship of Cardiorespiratory Fitness and Adiposity With Left Ventricular Strain in Middle-Age Adults (from the Dallas Heart Study). American Journal of Cardiology, 2017, 120, 1405-1409.	1.6	9
301	Noninvasive Cardiac Imaging and the Prediction of Heart Failure Progression inÂPreclinical Stage A/B Subjects. JACC: Cardiovascular Imaging, 2017, 10, 1504-1519.	5. 3	21
302	Classification and Prognostic Evaluation of Left Ventricular Remodeling in Patients With Asymptomatic Heart Failure. American Journal of Cardiology, 2017, 119, 71-77.	1.6	25
303	High sensitivity troponin T and I reflect mitral annular plane systolic excursion being assessed by cardiac magnetic resonance imaging. European Journal of Medical Research, 2017, 22, 38.	2,2	4
304	Biomarkers for heart failure: small molecules with high clinical relevance. Journal of Internal Medicine, 2018, 283, 530-543.	6.0	87

#	Article	IF	CITATIONS
305	Association between layer-specific global longitudinal strain and adverse outcomes following acute coronary syndrome. European Heart Journal Cardiovascular Imaging, 2018, 19, 1334-1342.	1.2	43
306	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. American Journal of Cardiology, 2018, 121, 615-620.	1.6	10
308	2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal, 2018, 7, 55-66.	2.4	165
309	The Association Between Depressive Symptoms and N-Terminal Pro–B-Type Natriuretic Peptide With Functional Status in Patients With Heart Failure. Journal of Cardiovascular Nursing, 2018, 33, 378-383.	1.1	11
310	Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 450-458.	0.7	21
311	Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes. European Journal of Heart Failure, 2018, 20, 385-394.	7.1	39
312	High sensitivity troponin T and I reflect left atrial function being assessed by cardiac magnetic resonance imaging. Annals of Clinical Biochemistry, 2018, 55, 264-275.	1.6	2
313	LV Mass Independently Predicts Mortality and Need for Future Revascularization inÂPatients Undergoing Diagnostic Coronary Angiography. JACC: Cardiovascular Imaging, 2018, 11, 423-433.	5.3	27
314	Early prediction of cardiac resynchronization therapy response by non-invasive electrocardiogram markers. Medical and Biological Engineering and Computing, 2018, 56, 611-621.	2.8	1
315	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	7.1	91
316	Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart, 2018, 104, 971-977.	2.9	323
317	Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study. Journal of Clinical Oncology, 2018, 36, 2980-2987.	1.6	37
318	Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 764-774.	3.8	18
319	Screening for Atherosclerotic Cardiovascular Disease in Asymptomatic Individuals. , 2018, , 459-478.		2
321	OBSOLETE: Biomarkers: Population Screening and Risk-Stratification. , 2018, , .		0
322	OBSOLETE: Stage B Heart Failure. , 2018, , .		0
323	Feasibility of biventricular volume and function assessment using first-pass gated 150-water PET. EJNMMI Research, 2018, 8, 92.	2.5	8
324	Ejection Fraction Pros and Cons. Journal of the American College of Cardiology, 2018, 72, 2360-2379.	2.8	156

#	Article	IF	Citations
325	Cancer and the Broken Heart. Journal of Infusion Nursing, 2018, 41, 229-240.	2.3	6
326	Echocardiography in Heart Failure. , 2018, , 619-642.		1
327	Echocardiography Evaluation of Left Ventricular Systolic Function, Systolic Dysfunction, and Ventricular Dyssynchrony., 2018, , 127-140.		0
328	Hemodynamic Patterns Identified by Impedance Cardiography Predict Mortality in the General Population: The PREVENCION Study. Journal of the American Heart Association, 2018, 7, e009259.	3.7	17
329	Impact of left ventricular concentricity on long-term mortality in a hospital-based population in Japan. PLoS ONE, 2018, 13, e0203227.	2.5	9
330	Cardio-oncology: protecting the heart from curative breast cancer treatment. Gland Surgery, 2018, 7, 350-365.	1.1	9
331	Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in highâ€risk populations? Insights from the DAVIDâ€Berg study. European Journal of Heart Failure, 2018, 20, 1540-1548.	7.1	11
332	Amiodarone-Induced Thyrotoxicosis. Clinical Nuclear Medicine, 2018, 43, 655-662.	1.3	17
333	Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy. JACC: Cardiovascular Imaging, 2018, 11, 1122-1131.	5.3	62
334	Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?. Current Oncology Reports, 2018, 20, 61.	4.0	39
335	Heart Failure with Mid-Range Ejection Fraction - State of the Art. Arquivos Brasileiros De Cardiologia, 2019, 112, 784-790.	0.8	12
336	<p>Prognostic implications of left ventricular strain by speckle-tracking echocardiography in the general population: a meta-analysis</p> . Vascular Health and Risk Management, 2019, Volume 15, 229-251.	2.3	32
337	Association between reduced myocardial contraction fraction and cardiovascular disease outcomes: The Multi-Ethnic Study of Atherosclerosis. International Journal of Cardiology, 2019, 293, 10-16.	1.7	16
339	Isolated Mitral Valve Repair in Patients with Reduced Left Ventricular Ejection Fraction. Annals of Thoracic and Cardiovascular Surgery, 2019, 25, 326-335.	0.8	4
340	Innovations in emerging markets: the case of mobile money. Industrial and Corporate Change, 2019, , .	2.8	12
341	A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure. International Heart Journal, 2019, 60, 1123-1130.	1.0	8
342	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019, 140, e294-e324.	1.6	342
343	Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy. American Journal of Cardiology, 2019, 124, 789-794.	1.6	17

#	ARTICLE	IF	CITATIONS
344	Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clinical Breast Cancer, 2019, 19, 259-267.e1.	2.4	22
345	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 2019, 25, 584-619.	1.7	56
346	70-year legacy of the Framingham Heart Study. Nature Reviews Cardiology, 2019, 16, 687-698.	13.7	143
347	Association of Arsenic Exposure With Cardiac Geometry and Left Ventricular Function in Young Adults. Circulation: Cardiovascular Imaging, 2019, 12, e009018.	2.6	34
348	Awareness and appropriateness of the management of preclinical heart failure in outpatient clinics in Italy: Insights from the VASTISSIMO study - EValuation of the AppropriateneSs of The preclInical phase (Stage A and Stage B) of Heart Fallure Management in Outpatient Clinics in Italy. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	3
349	Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in LeftÂVentricular Noncompaction. JACC: Cardiovascular Imaging, 2019, 12, 2141-2151.	5. 3	84
350	Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography. Anticancer Research, 2019, 39, 1667-1673.	1.1	21
351	Utility and limitations of ejection fraction and of diastolic dysfunction in heart failure patients. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	2
352	Ratio of Transmitral Early Filling Velocity to Early Diastolic Strain Rate as a Predictor of Cardiovascular Morbidity and Mortality Following Acute Coronary Syndrome. American Journal of Cardiology, 2019, 123, 1776-1782.	1.6	7
353	Interactive role of diastolic dysfunction and ventricular remodeling in asymptomatic subjects at increased risk of heart failure. International Journal of Cardiovascular Imaging, 2019, 35, 1231-1240.	1.5	9
354	Biomarkers of Cardiac Health and Disease. Critical Reviews in Biomedical Engineering, 2019, 47, 395-407.	0.9	1
356	Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic To Translational Science, 2019, 4, 962-972.	4.1	3
357	The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity. Cardiology in Review, 2019, 27, 256-259.	1.4	33
358	Breast Cancer and Heart Failure. Heart Failure Clinics, 2019, 15, 65-75.	2.1	10
359	Evidence-Based Management of the Patient with Congestive Heart Failure. Contemporary Cardiology, 2019, , 449-465.	0.1	0
360	Preventive use of carvedilol for anthracycline-induced cardiotoxicity: aÂsystematic review and meta-analysis of randomized controlled trials. Herz, 2020, 45, 1-14.	1.1	8
361	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	3.6	36
362	Accuracy of Cardiac Nurse Acquired and Measured Three-Dimensional Echocardiographic Left Ventricular Ejection Fraction: Comparison to Echosonographer. Heart Lung and Circulation, 2020, 29, 703-709.	0.4	2

#	Article	IF	CITATIONS
363	Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling. Journal of the American Society of Echocardiography, 2020, 33, 72-81.e6.	2.8	13
364	ECG Al-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial. American Heart Journal, 2020, 219, 31-36.	2.7	50
365	Prognostic value of right ventricular free wall longitudinal strain in a large cohort of outpatients with left-side heart disease. European Heart Journal Cardiovascular Imaging, 2020, 21, 1013-1021.	1.2	41
366	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. European Heart Journal Cardiovascular Imaging, 2020, 21, 1405-1411.	1.2	3
367	Sex Differences in Cardiovascular Aging and Heart Failure. Current Heart Failure Reports, 2020, 17, 409-423.	3.3	36
368	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3427-e3436.	3.6	13
369	Running away from cardiovascular disease at the right speed: The impact of aerobic physical activity and cardiorespiratory fitness on cardiovascular disease risk and associated subclinical phenotypes. Progress in Cardiovascular Diseases, 2020, 63, 762-774.	3.1	16
370	Clinical Characteristics of Patients with Different N-Terminal Probrain Natriuretic Peptide Levels after Hematopoietic Stem Cell Transplantation. Disease Markers, 2020, 2020, 1-7.	1.3	0
371	Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseases. International Journal of Cardiology, 2020, 307, 87-93.	1.7	2
372	Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2020, 38, 3851-3862.	1.6	25
373	Comparison between Spironolactone and Eplerenone on LV Systolic Function in Patients with Chronic Heart Failure. University Heart Journal, 2020, 16, 65-70.	0.0	1
374	Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Research and Treatment, 2020, 182, 333-343.	2.5	28
375	Left ventricular contractile performance and heart failure in patients with left ventricular ejection fraction more than 40%. Heart and Vessels, 2020, 35, 1689-1698.	1.2	3
376	Artificial Intelligence-Enabled ECG: a Modern Lens on an Old Technology. Current Cardiology Reports, 2020, 22, 57.	2.9	23
377	Association of Left Ventricular Ejection Fraction with Mortality and Hospitalizations. Journal of the American Society of Echocardiography, 2020, 33, 802-811.e6.	2.8	37
378	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiology, 2020, 16, 227-236.	1.2	16
379	Temporal changes in left ventricular ejection fraction and their prognostic impacts in patients with Stage B heart failure. International Journal of Cardiology, 2020, 306, 123-132.	1.7	3
380	Prognosis of "pre-heart failure―clinical phenotypes. PLoS ONE, 2020, 15, e0231254.	2.5	1

#	Article	IF	CITATIONS
381	The Epidemiology of Congestive Heart Failure: Contributions from the Framingham Heart Study. Global Heart, 2013, 8, 77.	2.3	84
382	Left ventricle function assessment using gated first-pass 18F-FDG PET: Validation against equilibrium radionuclide angiography. Journal of Nuclear Cardiology, 2021, 28, 594-603.	2.1	11
383	Clinical and echocardiographic characteristics of patients with preserved versus mid-range ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 503-508.	1.5	1
384	Cardiac MRI Reveals Late Diastolic Changes in Left Ventricular Relaxation Patterns During Healthy Aging. Journal of Magnetic Resonance Imaging, 2021, 53, 766-774.	3.4	5
385	Evolution of Myocardial Dysfunction in Asymptomatic Patients at Risk of HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 350-361.	5.3	11
386	Feasibility, Reproducibility, and Clinical Implications of the Novel Fully Automated Assessment for Global Longitudinal Strain. Journal of the American Society of Echocardiography, 2021, 34, 136-145.e2.	2.8	26
387	Clinical characteristics and outcomes of black African heart failure patients with preserved, midâ€range, and reduced ejection fraction: a post hoc analysis of the THESUSâ€HF registry. ESC Heart Failure, 2021, 8, 238-249.	3.1	5
388	Epidemiology of the inherited cardiomyopathies. Nature Reviews Cardiology, 2021, 18, 22-36.	13.7	117
389	The prognostic role of high-sensitivity cardiac troponin T over time in ischemic and non-ischemic heart failure. Postepy W Kardiologii Interwencyjnej, 2021, 17, 54-59.	0.2	1
391	The Role of Echocardiography in Heart Failure Today. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2021, 5, 16.	0.1	0
392	Correlation between left ventricular diastolic dysfunction and dyslipidaemia in asymptomatic patients with new-onset type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine, 2021, 33, .	0.9	4
393	Mid-term outcomes of coronary artery bypass grafting in patients with mild left ventricular systolic dysfunction: a multicentre retrospective cohort study. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 855-863.	1.1	0
394	Association of lung diffusion capacity with cardiac remodeling and risk of heart failure: The Framingham heart study. PLoS ONE, 2021, 16, e0246355.	2.5	0
395	Sarcopenia in heart failure: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 1007-1017.	3.1	65
396	Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology, 2021, 18, 465-478.	13.7	298
397	The Role of LVOT-VTI Measurement in the Evaluation of Systolic Heart Function in Pulmonary ICU Patients. Current Respiratory Medicine Reviews, 2021, 16, 234-239.	0.2	0
398	Association between instrumental activities of daily living with the change in left ventricular function in older patients with cardiovascular disease. Heart and Vessels, 2021, 36, 1298-1305.	1.2	1
399	Importancia de la cardiooncologÃa. Cómo detectar la insuficiencia cardiaca subclÃnica. Archivos De Cardiologia De Mexico, 2021, 91, 229-234.	0.2	0

#	Article	IF	CITATIONS
400	Study of correlation between 2D echocardiographic assessment of right ventricle and outcome of acute heart failure patients. Heliyon, 2021, 7, e06807.	3.2	0
401	Stage A Heart Failure. Heart Failure Clinics, 2021, 17, 167-177.	2.1	4
402	Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007216.	2.2	7
403	Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Medicine, 2021, 10, 3964-3973.	2.8	14
404	Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function. Indian Heart Journal, 2021, 73, 372-375.	0.5	4
405	Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nature Medicine, 2021, 27, 815-819.	30.7	154
406	A Need for Even More Evidence-Based Comparative Studies in Cardio-Oncology?. JACC: Cardiovascular Imaging, 2021, 14, 1081-1083.	5.3	0
407	CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. Cardio-Oncology, 2021, 7, 17.	1.7	9
408	Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. Current Cardiology Reports, 2021, 23, 86.	2.9	5
409	Framingham Heart Study. Journal of the American College of Cardiology, 2021, 77, 2680-2692.	2.8	35
410	Cost Effectiveness of an Electrocardiographic Deep Learning Algorithm to Detect Asymptomatic Left Ventricular Dysfunction. Mayo Clinic Proceedings, 2021, 96, 1835-1844.	3.0	15
411	Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 377-386.	2.1	5
412	CaracterÃsticas e Tendências na Mortalidade em Diferentes Fenótipos de Insuficiência CardÃaca na Atenção Primária. Arquivos Brasileiros De Cardiologia, 2021, 117, 300-306.	0.8	4
413	Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiological Reports, 2021, 9, e14974.	1.7	3
414	Thyroidectomy in patients with amiodarone-induced thyrotoxicosis. Vestnik Khirurgii Imeni I I Grekova, 2021, 180, 42-49.	0.2	0
415	Deep learning analysis of resting electrocardiograms for the detection of myocardial dysfunction, hypertrophy, and ischaemia: a systematic review. European Heart Journal Digital Health, 2021, 2, 416-423.	1.7	23
416	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports, 2021, 2, 100224.	1.1	6
417	Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?. Frontiers in Cardiovascular Medicine, 2021, 8, 744243.	2.4	4

#	Article	IF	CITATIONS
418	Biomarkers in Acute Heart Failure Syndromes: An Update. Current Cardiology Reviews, 2021, 17, .	1.5	1
419	Machine Learning-Derived Echocardiographic Phenotypes PredictÂHeartÂFailure Incidence in Asymptomatic Individuals. JACC: Cardiovascular Imaging, 2022, 15, 193-208.	5.3	39
420	Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age. Future Cardiology, 2021, 17, 1131-1142.	1.2	9
421	Artificial Intelligence–Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population. Mayo Clinic Proceedings, 2021, 96, 2576-2586.	3.0	15
422	Strain imaging applications and techniques. , 2022, , 1-19.		2
423	Evaluation of Systolic and Diastolic LV Function. , 2010, , 307-322.		1
424	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	3.9	3
425	Fractal Diagnostic Generalization of the Left Ventricular Cardiac Morphology: Moderate and Severe Abnormalities from Ventriculogram. Revista Universitas Medica, 2018, 59, .	0.1	2
426	Management of chronic heart failure in the older population. Journal of Geriatric Cardiology, 2014, 11, 329-37.	0.2	90
427	Blood Signature of Pre-Heart Failure: A Microarrays Study. PLoS ONE, 2011, 6, e20414.	2.5	23
428	Usefulness of Running Wheel for Detection of Congestive Heart Failure in Dilated Cardiomyopathy Mouse Model. PLoS ONE, 2013, 8, e55514.	2.5	13
429	One-Month Global Longitudinal Strain Identifies Patients Who Will Develop Pacing-Induced Left Ventricular Dysfunction over Time: The Pacing and Ventricular Dysfunction (PAVD) Study. PLoS ONE, 2017, 12, e0162072.	2.5	20
430	Accuracy of three-dimensional systolic dyssynchrony and sphericity indexes for identifying early left ventricular remodelling after acute myocardial infarction. Anatolian Journal of Cardiology, 2019, 22, 13-20.	0.9	4
431	Automated left heart chamber volumetric assessment using three-dimensional echocardiography in Chinese adolescents. Journal of Animal Science and Technology, 2017, 4, 53-61.	2.5	10
432	Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review, 2020, 15, e13.	2.2	20
434	CABG for patients with heart dysfunction: when and why to refuse surgery. Minerva Cardioangiologica, 2018, 66, 551-561.	1.2	2
435	Imaging predictors of incident heart failure: a systematic review and meta-analysis. Journal of Cardiovascular Medicine, 2021, 22, 378-387.	1.5	7
436	Recognizing and Managing Asymptomatic Left Ventricular Dysfunction. Critical Care Nurse, 2008, 28, 20-37.	1.0	19

#	Article	IF	CITATIONS
437	Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer. South Asian Journal of Cancer, 2018, 07, 146-150.	0.6	3
438	Coronary artery disease detection - limitations of stress testing in left ventricular dysfunction. World Journal of Cardiology, 2017, 9, 304.	1.5	6
439	Left Ventricular Volume and Function Assessment: a Comparison Study between Echocardiography and Ventriculography. Archives of Cardiovascular Imaging, 2014, 2, .	0.2	1
441	Clinical characteristics and correlates of patients with heart failure with mid-range ejection fraction in southwest Nigeria. Annals of Clinical and Biomedical Research, 2021, 2, .	0.1	0
442	Prognostic Indicators and Assessment of Therapeutic Responses. , 2005, , 145-159.		0
443	Epidemiology and Prognosis in Chronic Heart Failure. Fundamental and Clinical Cardiology, 2006, , 1-22.	0.0	0
444	Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. Fundamental and Clinical Cardiology, 2006, , 525-544.	0.0	0
445	Epidemiologie: prevalentie, incidentie en prognose. , 2007, , 29-45.		0
446	Echocardiography in Heart Failure. , 2009, , 435-445.		0
447	Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding appropriately?. Journal of Clinical Oncology, 2009, 27, 9527-9527.	1.6	1
449	Evidence-Based Management of the Patient with Congestive Heart Failure., 2011,, 497-518.		0
450	Neuroimaging of Cardiovascular Disease. , 2011, , 215-255.		1
453	Prevalence and Aetiology of Heart Failure in Patients Seen at a Teaching Hospital in Ghana. Journal of Cardiovascular Diseases & Diagnosis, 2013, 01, .	0.0	11
454	Estrategias de intervención para mejorar la calidad de vida en pacientes con insuficiencia cardÃaca. Revista Chilena De CardiologÃa, 2013, 32, 134-140.	0.0	2
455	Inleiding: definitie en epidemiologie., 2015,, 1-13.		0
456	Use of cTn for Detection of More Chronic Disease States. , 2016, , 111-122.		0
457	Evaluation and Management of Heart Failure in Patients with Reduced Ejection Fraction., 0,, 153-153.		0
458	Stage B Heart Failure., 2018,, 456-464.		0

#	Article	IF	CITATIONS
459	Biomarkers: Population Screening and Risk-Stratification. , 2018, , 323-333.		0
460	Prevalence of Anemia and Interpretation of Hemoglobin Concentrations in Hospitalized Children from 6 Months to 5 Years of Age at the Hospital Universitario San Ignacio from January 1 to December 31, 2015. Revista Universitas Medica, 2018, 59, .	0.1	O
461	Association of change in 5-year N-terminal fragment of the prohormone brain-type natriuretic peptide with left ventricular structure and function in stable coronary disease. Journal of Cardiovascular Medicine, 2018, 19, 67-72.	1.5	3
462	Comments on the 2018 European Thyroid Association Guidelines for the management of amiodarone-associated thyroid dysfunction. Mìžnarodnij EndokrinologìÄnij Å⅓2urnal, 2018, 14, 251-262.	0.4	0
463	Immunological changes in patients with chronic heart failure. Journal of Clinical Medicine of Kazakhstan, 2018, 2, 9-13.	0.3	0
464	Profile of Hospitalized Hypertensives with Preserved and Reduced Left Ventricular Ejection Fraction in Nigeria. International Cardiovascular Forum Journal, 0, 14, .	1.1	0
465	Spironolactone Versus Eplerenone as Adjunctive Treatment in Patients with Heart Failure. Cardiology Open Access, 2019, 4, .	0.0	0
466	CARDIOVASCULAR COMPLICATIONS OF ANTITUMOR THERAPY FOR BREAST CANCER: DIAGNOSIS, PREVENTION AND TREATMENT. Siberian Journal of Oncology, 2021, 20, 138-148.	0.3	1
467	Awareness of patients regarding self-management of heart failure attending a tertiary care hospital of North India. International Journal of Noncommunicable Diseases, 2020, 5, 158.	0.2	0
471	Cardiovascular Diseases in Elders. , 2020, , 238-250.		0
472	The Effectiveness of a Deep Learning Model to Detect Left Ventricular Systolic Dysfunction from Electrocardiograms. International Heart Journal, 2021, 62, 1332-1341.	1.0	10
473	Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. European Heart Journal, 2022, 43, 1124-1137.	2.2	111
474	Cardiorenal Effects of Longâ€Term Phosphodiesterase V Inhibition in Pre–Heart Failure. Journal of the American Heart Association, 2022, 11, e022126.	3.7	1
475	Hemostatic status in women with breast cancer and cardiotoxicity associated to doxorubicin-based chemotherapy – A one-year follow-up study. Thrombosis Research, 2022, 211, 56-59.	1.7	3
476	Factors Associated with Echocardiographic Abnormalities in Patients with Chronic Kidney Disease in a Tertiary Hospital in Ivory Coast. Open Journal of Nephrology, 2022, 12, 36-47.	0.1	0
477	Prospective Longitudinal Characterization of the Relationship between Diabetes and Cardiac Structural and Functional Changes. Cardiology Research and Practice, 2022, 2022, 1-12.	1.1	4
478	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
479	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774

#	Article	IF	Citations
482	Association of orthostatic blood pressure response with incident heart failure: The Framingham Heart Study. PLoS ONE, 2022, 17, e0267057.	2.5	2
483	Low mechanoâ€energetic efficiency is associated with future left ventricular systolic dysfunction in hypertensives. ESC Heart Failure, 2022, 9, 2291-2300.	3.1	14
484	Regional Strain Score as Prognostic Marker of Cardiovascular Events From the Multi-Ethnic Study of Atherosclerosis (MESA). Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	6
485	Early surgery: a favorable prognosticator in amiodarone-induced thyrotoxicosis—a single-center experience with 53 cases. Updates in Surgery, 2022, 74, 1413-1418.	2.0	3
487	Cluster analysis of extracellular matrix biomarkers predicts the development of impaired systolic function within 1Âyear of acute myocardial infarction. Heart and Vessels, 2022, 37, 2029-2038.	1.2	1
488	A comparison of echocardiographic and circulating cardiac biomarkers for predicting incident cardiovascular disease. PLoS ONE, 2022, 17, e0271835.	2.5	2
489	Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. Circulation: Heart Failure, 2022, 15, .	3.9	5
490	Clinical characteristics of heart failure patients with mid-range ejection fraction. Acta Cardiologica, 2023, 78, 233-240.	0.9	2
491	Advances in Multimodality Imaging inÂCardio-Oncology. Journal of the American College of Cardiology, 2022, 80, 1560-1578.	2.8	20
492	Clinical trajectories and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function. Clinical Research in Cardiology, 0, , .	3.3	0
493	Physicians and Machine-Learning Algorithm Performance in Predicting Left-Ventricular Systolic Dysfunction from a Standard 12-Lead-Electrocardiogram. Journal of Clinical Medicine, 2022, 11, 6767.	2.4	2
494	Diagnostic usefulness of NT-proBNP in asymptomatic left ventricular dysunction in black hypertensive patients. Nigerian Journal of Cardiology, 2021, 18, 44.	0.2	0
495	Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1298-1307.	3.6	5
496	Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping. Heliyon, 2023, 9, e13509.	3.2	3
497	Artificial intelligence-enabled electrocardiographic screening for left ventricular systolic dysfunction and mortality risk prediction. Frontiers in Cardiovascular Medicine, $0,10,10$	2.4	4
498	Low incidence of cardiotoxicity in patients with <scp>nonâ€Hodgkin</scp> lymphoma receiving <scp>EPOCH</scp> after prior anthracycline exposure. European Journal of Haematology, 0, , .	2.2	0
499	Non-Valvular Atrial Fibrillation in Young Adults in Eastern India: A Clinico-Aetiological Retrospective Analysis in a Tertiary Care Hospital. Cureus, 2023, , .	0.5	0
500	Pre–Heart Failure Longitudinal ChangeÂinÂa Hispanic/Latino Population-Based Study. JACC: Heart Failure, 2023, , .	4.1	0

#	ARTICLE	IF	CITATIONS
501	Screening for Dilated Cardiomyopathy inÂAt-Risk First-Degree Relatives. Journal of the American College of Cardiology, 2023, 81, 2059-2071.	2.8	4
502	The War Against Heart Failure Hospitalizations. Cardiology Clinics, 2023, 41, 557-573.	2.2	2
503	Detection of left ventricular systolic dysfunction from single-lead electrocardiography adapted for portable and wearable devices. Npj Digital Medicine, 2023, 6, .	10.9	12
504	Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images. Circulation, 2023, 148, 765-777.	1.6	16
505	Association between systemic inflammatory response index and left ventricular remodeling and systolic dysfunction in atrial fibrillation patients. BMC Cardiovascular Disorders, 2023, 23, .	1.7	2
507	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. Cardiology and Therapy, 0, , .	2.6	0
509	Short review: novel concepts in the approach to patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2024, 47, 275-283.	3.3	3
510	Deep Learning Models for Predicting Left Heart Abnormalities From Single-Lead Electrocardiogram for the Development of Wearable Devices. Circulation Journal, 2023, 88, 146-156.	1.6	1
511	Burden, determinants, consequences and care of multimorbidity in rural and urbanising Telangana, India: protocol for a mixed-methods study within the APCAPS cohort. BMJ Open, 2023, 13, e073897.	1.9	0
512	Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction With the Use of Electrocardiographic Artificial Intelligence: A Cost-Effectiveness Approach. Canadian Journal of Cardiology, 2023, , .	1.7	0
513	Early referrals save lives in advanced heart failure. Journal of the American Association of Nurse Practitioners, 0, , .	0.9	0
514	Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors. Lancet Oncology, The, 2024, 25, 154-156.	10.7	0
516	Biometric contrastive learning for data-efficient deep learning from electrocardiographic images. Journal of the American Medical Informatics Association: JAMIA, 2024, 31, 855-865.	4.4	0
517	Analysis and Prediction of Heart Stroke Using Lstm Deep Learning Approach. , 2023, , .		0
518	Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among communityâ€dwelling adults without cardiovascular disease: The Dallas Heart Study. European Journal of Heart Failure, 2024, 26, 208-215.	7.1	0
519	An Update on the Prevalence of Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 13-26.	0.1	0